评估涉及抗胆碱能特性药物的多重用药风险
该研究基于英国生物银行社区队列(502,538人,基线年龄37-73岁,中位随访6.2年),使用10种常用抗胆碱能负荷(ACB)量表量化ACB,评估各量表与不良结局的关联及所识别人群的重叠情况。结果显示ACB与全因死亡/主要不良心血管事件(MACE)及所有次要结局显著相关,但不同量表识别的效应大小和人群存在差异,量表选择会影响临床或干预试验中需降低ACB的目标人群。
要点
- ACB与全因死亡/MACE及跌倒/骨折、痴呆/谵妄等次要结局显著相关。
- 不同量表识别的抗胆碱能药物使用比例(8%-17.6%)和效应大小存在差异。
- 量表选择影响临床实践中需降低ACB的目标人群识别。
核心结论
- 在中老年人群中,抗胆碱能负荷与不良结局相关,但不同量表识别的效应大小和人群不同。
研究设计与样本
- 对英国生物银行社区队列502,538名参与者(基线年龄37-73岁,中位随访6.2年)进行纵向分析,使用10种量表计算基线ACB,并链接国家死亡登记和医院事件统计。
主要发现
- 抗胆碱能药物使用比例因量表不同为8%至17.6%。
- 所有量表计算的ACB均与全因死亡/MACE显著相关,抗胆碱能药物量表关联最强(HR=1.12;95%CI 1.11-1.14,每评分增加1分)。
- ACB与所有次要结局显著相关,抗胆碱能对认知影响量表与痴呆/谵妄关联最强(HR=1.45;95%CI 1.3-1.61,每评分增加1分)。
关键数值与推荐
- 抗胆碱能药物使用比例:8%-17.6%(因量表而异)。
- 全因死亡/MACE:抗胆碱能药物量表HR=1.12(95%CI 1.11-1.14,每评分增加1分)。
- 痴呆/谵妄:抗胆碱能对认知影响量表HR=1.45(95%CI 1.3-1.61,每评分增加1分)。
临床怎么用
- 临床评估多重用药时,应关注药物的抗胆碱能特性,但需注意不同量表识别的风险人群和效应大小存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Anticholinergic burden (ACB), the cumulative effect of anticholinergic medications, is associated with adverse outcomes in older people but is less studied in middle-aged populations. Numerous scales exist to quantify ACB. The aims of this study were to quantify ACB in a large cohort using the 10 most common anticholinergic scales, to assess the association of each scale with adverse outcomes, and to assess overlap in populations identified by each scale. METHODS: We performed a longitudinal analysis of the UK Biobank community cohort (502,538 participants, baseline age: 37-73 years, median years of follow-up: 6.2). The ACB was calculated at baseline using 10 scales. Baseline data were linked to national mortality register records and hospital episode statistics. The primary outcome was a composite of all-cause mortality and major adverse cardiovascular event (MACE). Secondary outcomes were all-cause mortality, MACE, hospital admission for fall/fracture, and hospital admission with dementia/delirium. Cox proportional hazards models (hazard ratio [HR], 95% CI) quantified associations between ACB scales and outcomes adjusted for age, sex, socioeconomic status, body mass index, smoking status, alcohol use, physical activity, and morbidity count. RESULTS: Anticholinergic medication use varied from 8% to 17.6% depending on the scale used. For the primary outcome, ACB was significantly associated with all-cause mortality/MACE for each scale. The Anticholinergic Drug Scale was most strongly associated with mortality/MACE (HR = 1.12; 95% CI, 1.11-1.14 per 1-point increase in score). The ACB was significantly associated with all secondary outcomes. The Anticholinergic Effect on Cognition scale was most strongly associated with dementia/delirium (HR = 1.45; 95% CI, 1.3-1.61 per 1-point increase). CONCLUSIONS: The ACB was associated with adverse outcomes in a middle- to older-aged population. Populations identified and effect size differed between scales. Scale choice influenced the population identified as potentially requiring reduction in ACB in clinical practice or intervention trials.
引用
- Hanlon P, Quinn TJ, Gallacher KI, et al. Assessing Risks of Polypharmacy Involving Medications With Anticholinergic Properties. Ann Fam Med. 2020. PMID: 32152019. doi:10.1370/afm.2501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。